Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5635)
•••
Comment by Noteableon Jan 03, 2024 1:31pm
186 Views
Post# 35809062

RE:RE:RE:“Second mouse gets the cheese “

RE:RE:RE:“Second mouse gets the cheese “https://www.fiercebiotech.com/biotech/cg-oncology-plans-ipo-ahead-phase-3-bladder-cancer-drug-readout

CG’s use of an oncolytic virus to treat BCG-unresponsive NMIBC has drawn comparisons with Ferring, which was granted approval for an adenovirus vector-based gene therapy in the tumor type in late 2022. The Ferring product, Adstiladrin, differs in that it encodes interferon alfa-2b, turning bladder cells into interferon factories.

ONCY posters @ ASCO 2024 - Anne Noonan - CEACAM6 and IFITM3 as potential biomarkers.

Interferon-induced transmembrane protein 3 (IFITM3) is a protein that in humans is encoded by the IFITM3 gene. Low levels or the removal of IFITM3 allows for the multiplication of viruses.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities